Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04370704 · ClinicalTrials.gov registry record · Phase 1
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
A Phase 1 study of Melanoma, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 17
- Study locations
NCT04370704 is a Phase 1 study of Melanoma that has completed, run by Incyte Corporation. The registered enrollment target is 61 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (91% lower). The trial reports 17 study locations across 15 states.
The verdict
NCT04370704, a Phase 1 study of Melanoma, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 17
- Study locations
Study Summary
The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.
Conditions Studied
Interventions
- DRUG INCAGN02385
- DRUG INCAGN02390
- DRUG INCMGA00012.
Study Locations (17)
Florida
- University of Miami Sylvester Comprehensive Cancer Center - Miami
- H Lee Moffitt Cancer Center and Research - Tampa
Pennsylvania
- Penn State Hershey Cancer Institute - Hershey
- Hillman Cancer Center - Pittsburgh
California
- The Angeles Clinic and Research Institute - Los Angeles
Iowa
- University of Iowa - Iowa City
Maryland
- Cancer Center For Blood Disorders A Division of American Oncology Partners P.A - Bethesda
Missouri
- Washington University - St Louis
New Jersey
- John Theurer Cancer Center, Hackensack University Medical Center - Hackensack
New York
- Nyu Langone Laura and Isaac Perlmutter Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2020-07-27 |
| Est. Completion | 2025-08-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04370704
The ClinicalTrials.gov registry entry for NCT04370704 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (91% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 3 interventions - of which INCAGN02385 is the first listed.
NCT04370704 reports 17 study locations spanning 15 distinct geographic areas - top geographies include Florida, Pennsylvania, California.
Frequently Asked Questions
What is clinical trial NCT04370704 about?
NCT04370704 is a clinical study titled "Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies". The study will determine Recommended Phase 2 Dose for all study drugs, based on the safety and tolerability of the following combinations: INCAGN02385 + INCAGN02390 and INCAGN02385 + INCAGN02390 + INCMGA00012.
What is the current status of trial NCT04370704?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2020-07-27. Estimated completion is 2025-08-25.
What conditions does trial NCT04370704 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT04370704?
The interventions under investigation include: INCAGN02385 (DRUG), INCAGN02390 (DRUG), INCMGA00012. (DRUG).
Who is sponsoring clinical trial NCT04370704?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04370704 being conducted?
This trial has 17 study locations across California, Florida, Iowa, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.